secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2026-09-28T20:30:45+00:00
Accession:  0001104659-26-111391
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4.1-flash:cloud@v2

Gain Therapeutics CFO Gianluca Fuggetta resigns Sept 30; CEO Gene Mack named interim CFO
--------------------------------------------------------------------------------

- Gianluca Fuggetta, SVP of Finance and principal financial and accounting officer, notified the company on Sept 22, 2026 of his resignation effective Sept 30, 2026 to pursue other opportunities.
- Board appointed President and CEO Gene Mack as interim CFO effective Oct 1, 2026; he will also assume principal financial officer and principal accounting officer duties.
- Mack continues as President and CEO; the company said it is engaged in an ongoing search for a permanent replacement for the principal financial/accounting officer roles.
- Mack's compensatory and other material employment terms remain unchanged in connection with the interim CFO appointment.
- No arrangements or understandings between Mack and any other persons led to his selection, and no Item 404(a) related-party transactions were disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465926111391/0001104659-26-111391-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465926111391/tm2626106d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-111391

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer